. Author manuscript; available in PMC: 2006 May 17.

Published in final edited form as: Arch Ophthalmol. 2001 Oct;119(10):1417–1436. doi: 10.1001/archopht.119.10.1417

Table 7.

Effect of Treatment on Risk of Loss of VA Score of ≥15 Letters From Baseline in AMD Category 4 Eyes With Advanced Neovascular AMD^*

	Baseline VA 20/100 or better (n = 260)		Baseline VA 20/200 or better (n = 352)
Treatment	OR (99% CI)	PValue	OR (99% CI)	PValue
Antioxidants vs no antioxidants	0.54 (0.30–0.95)	.005	0.66 (0.40–1.07)	.03
Zinc vs no zinc	0.99 (0.56–1.74)	.96	1.10 (0.67–1.79)	.62
Antioxidants vs placebo	0.35 (0.15–0.81)	.001	0.56 (0.27–1.13)	.03
Zinc vs placebo	0.65 (0.28–1.50)	.18	0.93 (0.46–1.89)	.79
Antioxidants + zinc vs placebo	0.53 (0.23–1.24)	.05	0.72 (0.36–1.46)	.24
Total No. of participants with events	167		206

Eyes with geographic atrophy at baseline are excluded. Unadjusted analysis by repeated-measures logistic regression. VA indicates visual acuity; AMD, age-related macular degeneration; OR, odds ratio; and CI, confidence interval. P≤.01 is considered statistically significant.